Management of renal osteodystrophy in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 24, Issue 3, 2004, Pages 209-216

  Moe, Sharon M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium; Osteoporosis; Phosphorus; Renal osteodystrophy; Vitamin D

Indexed keywords

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; DOXERCALCIFEROL; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

BONE BIOPSY; CALCIUM BALANCE; COMPARATIVE STUDY; DIAGNOSTIC PROCEDURE; DIALYSATE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESEARCH; DRUG USE; HEMODIALYSIS PATIENT; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MEDICAL DECISION MAKING; METABOLIC BONE DISEASE; PATHOGENESIS; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 2942668040     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080402400302     Document Type: Review

References (71)

1. Hui SL, Slemenda CW, Johnston CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81: 1804-9.
2. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993; 43:436-42.
3. Carmen Sanchez M, Auxiliadora Bajo M, Selgas R, Mate A, Millan I, Eugenia Martinez M, et al. Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 2000; 36: 953-61.
4. Changsirikulchai S, Domrongkitchaiporn S, Sirikulchayanonta V, Ongphiphadhanakul B, Kunkitti N, Stitchantrakul W, et al. Renal osteodystrophy in Ramathibodi Hospital: histomorphometry and clinical correlation. J Med Assoc Thai 2000; 83:1223-32.
5. Gal-Moscovici A, Popovtzer MM. Parathyroid hormone-independent osteoclastic resorptive bone disease: a new variant of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 2002; 17:620-4.
6. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 85:S73-8.
7. Heaf JG, Lokkegard H. Parathyroid hormone during maintenance dialysis: influence of low calcium dialysate, plasma albumin and age. J Nephrol 1998; 11: 203-10.
8. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res 1995; 10: 149-56.
9. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992; 38:S62-7.
10. Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, De Bonis E, et al. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994; 9:517-23.
11. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-6.
12. Couttenye MM, D'Haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 1997; 12:2144-50.
13. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58:753-61.
14. Malluche HH, Mawad H, Trueba D, Monier-Faugere MC. Parathyroid hormone assays - evolution and revolutions in the care of dialysis patients. Clin Nephrol 2003; 59:313-18.
15. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46:855-61.
16. Llach F, Felsenfeld AJ, Coleman MD, Keveney JJ Jr, Pederson JA, Medlock TR. The natural course of dialysis osteomalacia. Kidney Int Suppl 1986; 18:S74-9.
17. Kurz P, Tsobanelis T, Roth P, Werner E, Ewald U, Grutzmacher P, et al. Differences in calcium kinetic pattern between CAPD and HD patients. Clin Nephrol 1995; 44:255-61.
18. Schmitt CP, Huber D, Mehls O, Maiwald J, Stein G, Veldhuis JD, et al. Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol 1998; 9:1832-44.
19. Schmitt CP, Schaefer F, Huber D, Zahn I, Veldhuis JD, Ritz E, et al. 1,25(OH)2-vitamin D3 reduces spontaneous and hypocalcemia-stimulated pulsatile component of parathyroid hormone secretion. J Am Soc Nephrol 1998; 9:54-62.
20. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 1997; 99: 2961-70.
21. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102:1627-33.
22. Reeve J. PTH: a future role in the management of osteoporosis? [Editorial] J Bone Miner Res 1996; 11:440-5.
23. Montenegro J, Saracho R, Gonzalez O, Moina I, Martinez I. Reversibility of parathyroid gland suppression in CAPD patients with low i-PTH levels. Clin Nephrol 1997; 48:359-63.
24. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, et al. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 1993; 44:860-6.
25. Moe SM, Peterson JM, Murphy CL, Johnson EA, Deeg M. Sevelamer HCl improves parathyroid hormone (PTH) and bone function in peritoneal dialysis (PD) patients with probable low turnover bone disease [Abstract]. Am J Kidney Dis 2001; 37:A25.
26. Delmez JA, Slatopolsky E, Martin KJ, Gearing BN, Harter HR. Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int 1982; 21:862-7.
27. Rodriguez-Carmona A, Selgas R, Martinez ME, Orti F, Miguel JL, Salinas M, et al. Characteristics of the peritoneal mass transfer of parathormone in patients under continuous ambulatory peritoneal dialysis therapy. Nephron 1984; 37:21-4.
28. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33:287-93.
29. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36:1115-21.
30. Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38:1351-7.
31. Dimkovic NB, Bargman J, Vas S, Oreopoulos DG. Normal or low initial PTH levels are not a predictor of morbidity/mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2002; 22:204-10.
32. K/DOQI NKF. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3)S1-S201.
33. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26:836-44.
34. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26:622-31.
35. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60:1460-8.
36. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, et al. PTH 1-84 and PTH "7-84" in the non-invasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40:348-54.
37. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003; 63: 1801-8.
38. Couttenye MM, D'Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11:1065-72.
39. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990; 86:1313-19.
40. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478-83.
41. Chertow GM, Lowrie EG, Lew NL. Mineral metabolism and mortality in dialysis [Abstract]. J Am Soc Nephrol 2000; 11:A2958.
42. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14:159-68.
43. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18:1731-40.
44. Bender FH, Bernardini J, Piraino B. Calcium mass transfer with dialysate containing 1.25 and 1.75 mmol/L calcium in peritoneal dialysis patients. Am J Kidney Dis 1992; 20:367-71.
45. Coburn JW, Koppel MH, Brickman AS, Massry SG. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 1973; 3:264-72.
46. Parker A, Nolph KD. Magnesium and calcium mass transfer during continuous ambulatory peritoneal dialysis. Trans Am Soc Artif Intern Organs 1980; 26: 194-6.
47. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997; 29:641-9.
48. Heaney RP, Saville PD, Recker RR. Calcium absorption as a function of calcium intake. J Lab Clin Med 1975; 85:881-90.
49. Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1982; 21:849-61.
50. Hutchison A, Gokal R. Calcium content in automated peritoneal dialysis solutions. Contrib Nephrol 1999; 129:168-76.
51. Delmez JA. Removal of phosphorus by peritoneal dialysis. Perit Dial Int 1993; 13(Suppl 2):S461-3.
52. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-14.
53. Kronenberg F, Lingenhel A, Neyer U, Lhotta K, Konig P, Auinger M, et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 2003; 84:S113-16.
54. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-52.
55. Moe SM, O'Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P, et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 2003; 18:1152-8.
56. Stompor T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wojcik K, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003; 41:203-11.
57. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42:96-107.
58. Aloni Y, Shany S, Chaimovitz C. Losses of 25-hydroxy-vitamin D in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis. Miner Electrolyte Metab 1983; 9:82-6.
59. Shany S, Rapoport J, Goligorsky M, Yankowitz N, Zuili I, Chaimovitz C. Losses of 1,25- and 24,25-dihydroxy-cholecalciferol in the peritoneal fluid of patients treated with continuous ambulatory peritoneal dialysis. Nephron 1984; 36:111-13.
60. Delmez JA, Dougan CS, Gearing BK, Rothstein M, Windus DW, Rapp N, et al. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 1987; 31:795-9.
61. Jones CL, Vieth R, Spino M, Ledermann S, Kooh SW, Balfe J, et al. Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. Clin Nephrol 1994; 42: 44-9.
62. Joffe P, Cintin C, Ladefoged SD, Rasmussen SN. Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. Clin Nephrol 1994; 41:364-9.
63. Sprague SM, Ho LT. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient. Clin Nephrol 2002; 58:155-60.
64. Qiu J, Smolenski O, Fadem S, Kant K, Borneman L, Hippensteel R, et al. Rapid control of secondary hyperparathyroidism with paricalcitol (Zeplar®) capsule in patients on peritoneal dialysis [Abstract]. J Am Soc Nephrol 2003; 14:484A.
65. Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26:852-60.
66. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349:446-56.
67. Moe SM, Kraus MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 1998; 13:1234-41.
68. Schaefer K, Umlauf E, von Herrath D. Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis 1992; 19: 460-4.
69. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63:248-54.
70. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14:575-83.
71. Lindberg J, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Phase 3 experience with cinacalcet HCl in hemodialysis (HD) and peritoneal dialysis (PD) patients with secondary HPT [Abstract]. J Am Soc Nephrol 2003; 14:463A.